• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Removing a protein ‘signal jammer’ improves tumor response to immunotherapy

March 19, 2025
in Medical Research
Reading Time: 5 mins read
A A
0
Removing a protein 'signal jammer' improves tumor response to immunotherapy
6
SHARES
12
VIEWS
Share on FacebookShare on Twitter


Removing a protein 'signal jammer' improves tumor response to immunotherapy
IFNγ signaling does not induce cell death in non-tumorigenic cells lacking VDAC2. Credit: Nature (2025). DOI: 10.1038/s41586-025-08732-6

Targeted inhibition of a “signal jammer” protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein voltage-dependent anion channel 2 (VDAC2) as a signal jammer to prevent the body’s anticancer systems from communicating with the immune system.

The research also reveals the unexpected central role that mitochondria, cellular organelles involved in energy production, play in this anticancer and immune communication. This proof-of-principle from St. Jude Children’s Research Hospital may guide future immunotherapy for cancers that have so far been largely resistant to such treatments, including pediatric solid tumors.

Successful solid tumors find ways to bypass or hide from the immune system, limiting immunotherapies’ effects. In a healthy individual, T cells find cancer cells and release the protein interferon-gamma, a potent cytokine that stops tumor growth. However, interferon-gamma has limited effects on directly killing tumors in many cancers, which impedes anticancer therapies. The St. Jude scientists showed that removing VDAC2 can assist in overcoming the effects of interferon-gamma.

Removing VDAC2 in the presence of interferon-gamma increased cancer cell death directly and made tumors more inflammatory, thereby making tumors more vulnerable to different kinds of immunotherapy. These findings provide evidence for future therapeutic development for inhibitors of proteins like VDAC2 that have dual protective roles in impeding tumor cell death and inflammatory rewiring of cancer cells.

“Despite the curative potential of immunotherapy, many patients still don’t respond to it,” said corresponding author Hongbo Chi, Ph.D., St. Jude Department of Immunology. “We discovered a very potent way to enable cancers to be more responsive to T cells and immunotherapy by targeting proteins with dual protective roles in the tumor.”

To identify the proteins most responsible for helping tumors resist immunotherapy, the researchers used CRISPR-Cas9 screens to target metabolism-related genes in cancer cells. They then exposed those modified cancer cells to interferon-gamma or T-cell treatment to find which genes’ absence reduced tumor growth or promoted their killing. Through these screens, removing VDAC2 from tumors had a profound effect, drastically increasing sensitivity to immunotherapies in previously resistant mouse models of skin, colon and liver cancers.

Removing a protein 'signal jammer' improves immunotherapy
(L to R) Corresponding author Hongbo Chi, co-first author Sujing Yuan and co-first author Renqiang Sun, Ph.D., Ph.D., St. Jude Department of Immunology. Credit: St. Jude Children’s Research Hospital

VDAC2 ‘jams’ calls in and out of tumors

With those initial results, the researchers investigated how VDAC2 protects resistant tumors. They showed that VDAC2 can act like a cell phone jammer. It prevents tumor cells from receiving calls from and sending calls to the immune system. However, when the scientists removed VDAC2, tumor cells better received the calls from interferon-gamma produced by T cells, causing the tumor cells to activate cell death pathways. These received calls also enabled tumor cells to activate fast-acting “innate” signaling pathways.

Specifically, targeting VDAC2 caused tumor cells to release inflammatory molecules called type I interferons, which sent out calls from the tumor cells to the adaptive immune system, much like how the innate immune system mediates early immune responses to infections.

“Normally, type I interferons are produced as part of the early innate immune system and act before the adaptive immune cells, such as T cells, arrive,” said co-first author Renqiang Sun, Ph.D., St. Jude Department of Immunology.

“We were excited and surprised to find that this process can work in reverse, as T cells, via interferon-gamma, led to an increase in innate-like immune activation in cancer cells that then led to more anticancer effects. These observations may help us find novel ways to improve immunotherapy.”

An unexpected role for mitochondria

Unexpectedly, the jammed signal within cancer cells was coming from mitochondria, which have their own unique DNA. Mitochondria coordinate growth and death signals related to energy production. When cancer cells lacked VDAC2, interferon-gamma could break open mitochondria, causing them to release their unique DNA and trigger type I interferon production. That mitochondrial DNA activated special DNA sensors, cGAS–STING signaling. The mitochondria also released the molecule cytochrome c, which activates cell death pathways directly, causing some tumor cells to self-destruct.

“We showed that mitochondria are much more important in antitumor immunity than previously thought,” said co-first author Sujing Yuan, Ph.D., St. Jude Department of Immunology. “This opens up new avenues for researchers to modify mitochondrial function in tumors to make them more vulnerable to immunotherapies and other treatments.”

No drugs currently exist to inhibit VDAC2 specifically. However, the study provides insight that could lead to inhibitors of VDAC2 or parts of its signaling pathway. It also serves as a proof-of-principle for targeting these signal jammer proteins.

“We’ve uncovered a new theme in potential drug targets within tumors,” Chi said. “Targeting signaling molecules that protect tumor cells in multiple ways, such as preventing inflammation and cell death in the case of VDAC2, is an exciting direction to explore for therapeutic intervention by making tumors more responsive to T cells and enhancing immunotherapy efficacy.”

More information:
Sujing Yuan et al, VDAC2 loss elicits tumour destruction and inflammation for cancer therapy, Nature (2025). DOI: 10.1038/s41586-025-08732-6

Provided by
St. Jude Children’s Research Hospital


Citation:
Removing a protein ‘signal jammer’ improves tumor response to immunotherapy (2025, March 19)
retrieved 19 March 2025
from https://medicalxpress.com/news/2025-03-protein-jammer-tumor-response-immunotherapy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Removing a protein 'signal jammer' improves tumor response to immunotherapy
IFNγ signaling does not induce cell death in non-tumorigenic cells lacking VDAC2. Credit: Nature (2025). DOI: 10.1038/s41586-025-08732-6

Targeted inhibition of a “signal jammer” protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein voltage-dependent anion channel 2 (VDAC2) as a signal jammer to prevent the body’s anticancer systems from communicating with the immune system.

The research also reveals the unexpected central role that mitochondria, cellular organelles involved in energy production, play in this anticancer and immune communication. This proof-of-principle from St. Jude Children’s Research Hospital may guide future immunotherapy for cancers that have so far been largely resistant to such treatments, including pediatric solid tumors.

Successful solid tumors find ways to bypass or hide from the immune system, limiting immunotherapies’ effects. In a healthy individual, T cells find cancer cells and release the protein interferon-gamma, a potent cytokine that stops tumor growth. However, interferon-gamma has limited effects on directly killing tumors in many cancers, which impedes anticancer therapies. The St. Jude scientists showed that removing VDAC2 can assist in overcoming the effects of interferon-gamma.

Removing VDAC2 in the presence of interferon-gamma increased cancer cell death directly and made tumors more inflammatory, thereby making tumors more vulnerable to different kinds of immunotherapy. These findings provide evidence for future therapeutic development for inhibitors of proteins like VDAC2 that have dual protective roles in impeding tumor cell death and inflammatory rewiring of cancer cells.

“Despite the curative potential of immunotherapy, many patients still don’t respond to it,” said corresponding author Hongbo Chi, Ph.D., St. Jude Department of Immunology. “We discovered a very potent way to enable cancers to be more responsive to T cells and immunotherapy by targeting proteins with dual protective roles in the tumor.”

To identify the proteins most responsible for helping tumors resist immunotherapy, the researchers used CRISPR-Cas9 screens to target metabolism-related genes in cancer cells. They then exposed those modified cancer cells to interferon-gamma or T-cell treatment to find which genes’ absence reduced tumor growth or promoted their killing. Through these screens, removing VDAC2 from tumors had a profound effect, drastically increasing sensitivity to immunotherapies in previously resistant mouse models of skin, colon and liver cancers.

Removing a protein 'signal jammer' improves immunotherapy
(L to R) Corresponding author Hongbo Chi, co-first author Sujing Yuan and co-first author Renqiang Sun, Ph.D., Ph.D., St. Jude Department of Immunology. Credit: St. Jude Children’s Research Hospital

VDAC2 ‘jams’ calls in and out of tumors

With those initial results, the researchers investigated how VDAC2 protects resistant tumors. They showed that VDAC2 can act like a cell phone jammer. It prevents tumor cells from receiving calls from and sending calls to the immune system. However, when the scientists removed VDAC2, tumor cells better received the calls from interferon-gamma produced by T cells, causing the tumor cells to activate cell death pathways. These received calls also enabled tumor cells to activate fast-acting “innate” signaling pathways.

Specifically, targeting VDAC2 caused tumor cells to release inflammatory molecules called type I interferons, which sent out calls from the tumor cells to the adaptive immune system, much like how the innate immune system mediates early immune responses to infections.

“Normally, type I interferons are produced as part of the early innate immune system and act before the adaptive immune cells, such as T cells, arrive,” said co-first author Renqiang Sun, Ph.D., St. Jude Department of Immunology.

“We were excited and surprised to find that this process can work in reverse, as T cells, via interferon-gamma, led to an increase in innate-like immune activation in cancer cells that then led to more anticancer effects. These observations may help us find novel ways to improve immunotherapy.”

An unexpected role for mitochondria

Unexpectedly, the jammed signal within cancer cells was coming from mitochondria, which have their own unique DNA. Mitochondria coordinate growth and death signals related to energy production. When cancer cells lacked VDAC2, interferon-gamma could break open mitochondria, causing them to release their unique DNA and trigger type I interferon production. That mitochondrial DNA activated special DNA sensors, cGAS–STING signaling. The mitochondria also released the molecule cytochrome c, which activates cell death pathways directly, causing some tumor cells to self-destruct.

“We showed that mitochondria are much more important in antitumor immunity than previously thought,” said co-first author Sujing Yuan, Ph.D., St. Jude Department of Immunology. “This opens up new avenues for researchers to modify mitochondrial function in tumors to make them more vulnerable to immunotherapies and other treatments.”

No drugs currently exist to inhibit VDAC2 specifically. However, the study provides insight that could lead to inhibitors of VDAC2 or parts of its signaling pathway. It also serves as a proof-of-principle for targeting these signal jammer proteins.

“We’ve uncovered a new theme in potential drug targets within tumors,” Chi said. “Targeting signaling molecules that protect tumor cells in multiple ways, such as preventing inflammation and cell death in the case of VDAC2, is an exciting direction to explore for therapeutic intervention by making tumors more responsive to T cells and enhancing immunotherapy efficacy.”

More information:
Sujing Yuan et al, VDAC2 loss elicits tumour destruction and inflammation for cancer therapy, Nature (2025). DOI: 10.1038/s41586-025-08732-6

Provided by
St. Jude Children’s Research Hospital


Citation:
Removing a protein ‘signal jammer’ improves tumor response to immunotherapy (2025, March 19)
retrieved 19 March 2025
from https://medicalxpress.com/news/2025-03-protein-jammer-tumor-response-immunotherapy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.


Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

In new ‘Buena Vista Social Club’ musical, a legendary Cuban album comes to life onstage

Next Post

Jury finds Greenpeace must pay hundreds of millions in case over Dakota Access protest activities

Related Posts

brain tumor

Nurses not satisfied with Newton-Wellesley study

May 30, 2025
0
multiple myeloma

New standard of care emerges for multiple myeloma

May 30, 2025
4
Next Post
Jury finds Greenpeace must pay hundreds of millions in case over Dakota Access protest activities

Jury finds Greenpeace must pay hundreds of millions in case over Dakota Access protest activities

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0

Musk leaves White House with frustrations, little progress on debt

May 30, 2025
Providing a Legal Identity for All Should be Southeast Asia’s Next Big Migration Priority

Providing a Legal Identity for All Should be Southeast Asia’s Next Big Migration Priority – The Diplomat

May 30, 2025
Comedian Russell Brand pleads not guilty to rape – DW – 05/30/2025

Comedian Russell Brand pleads not guilty to rape – DW – 05/30/2025

May 30, 2025

How White South Africans Are Convincing the U.S. to Accept Them as Refugees

May 30, 2025

Recent News

Musk leaves White House with frustrations, little progress on debt

May 30, 2025
2
Providing a Legal Identity for All Should be Southeast Asia’s Next Big Migration Priority

Providing a Legal Identity for All Should be Southeast Asia’s Next Big Migration Priority – The Diplomat

May 30, 2025
2
Comedian Russell Brand pleads not guilty to rape – DW – 05/30/2025

Comedian Russell Brand pleads not guilty to rape – DW – 05/30/2025

May 30, 2025
4

How White South Africans Are Convincing the U.S. to Accept Them as Refugees

May 30, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Tennis players wonder if nasal strips aren't just for snoring anymore

Tennis players wonder if nasal strips aren’t just for snoring anymore

May 30, 2025

Musk leaves White House with frustrations, little progress on debt

May 30, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co